Tulio E Rodriguez MD
Hematologic Oncology
Director of Hematology, Bone Marrow Transplant and Cellular Therapy Program at City of Hope Chicago
Join to View Full Profile
160 E IllinoisChicago, IL 60611
Phone+1 847-748-0627
Dr. Rodriguez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Tulio Rodriguez is a hematologist specializing in hematologic oncology based in Chicago, IL. Dr. Rodriguez completed a residency in internal medicine at VA Caribbean Healthcare System and a fellowship in hematology and medical oncology at the University of Texas Health Science Center San Antonio. Currently, Dr. Rodriguez serves as the Division Director at City of Hope Chicago and as Director of Bone Marrow Transplant at Advocate Lutheran General Hospital. Dr. Rodriguez has expertise in areas such as amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and bone marrow transplantation. The provider has contributed to multiple publications, including studies on multiple myeloma and lymphoma, and actively participated in clinical trials focused on lymphoma and myeloma. Dr. Rodriguez has also received certifications consistent with CMS Meaningful Use standards.
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1993 - 1996
VA Caribbean Healthcare SystemResidency, Internal Medicine, 1990 - 1993
Pontificia Universidad Católica Madre y MaestraClass of 1987
Certifications & Licensure
TX State Medical License 1996 - 2027
IL State Medical License 2000 - 2026
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
Clinical Trials
- Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) Start of enrollment: 2004 Aug 01
- Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
- S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
Publications & Presentations
PubMed
- 1 citationsBCMA-targeting BiTE molecule AMG 420 in relapsed or refractory multiple myeloma: a phase 1b open-label expansion study.Cesar Rodriguez, Tulio Rodriguez, Alain Kentos, Christoph Driessen, Kazutaka Sunami
Leukemia & Lymphoma. 2025-11-01 - Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.Lori A Leslie, John H Baird, Ian W Flinn, Michael Tees, Daanish Hoda
American Journal of Cancer Research. 2025-01-01 - 10 citationsPersistent SARS-CoV-2 infectivity greater than 50 days in a Case Series of Allogeneic Peripheral Blood Stem Cell Transplant RecipientsAlice Han, Tulio E. Rodriguez, Eric T. Beck, Ryan F. Relich, Dioma U. Udeoji
Current Problems in Cancer. Case Reports. 2021-01-16
Press Mentions
Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-EscalationDecember 28th, 2024- Quads, Frailty, and the Future: Evolving Frontline Strategies in Multiple MyelomaDecember 20th, 2024
- Adding Isatuximab to Standard Backbone Prolongs PFS in MyelomaJune 14th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
